Galapagos NV Market Cap ($1.60 Billion)
Market Cap & Net Worth: Galapagos NV (GXEA)
Galapagos NV market cap. Galapagos NV (F:GXEA) has a market capitalization of $1.60 Billion (€1.37 Billion) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #6740 globally and #991 in its home market, demonstrating a 4.35% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Galapagos NV's stock price €28.80 by its total outstanding shares 65897071 (65.90 Million). Also see GXEA cash flow metrics for how efficiently the company converts equity into cash flow.
Galapagos NV Market Cap History (2015–2026)
Galapagos NV market cap history from 2015 to 2026. Data shows change from $4.36 Billion to $2.22 Billion (-3.44% CAGR). Check Galapagos NV stock quote for real-time trading data and today's change.
Galapagos NV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Galapagos NV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore GXEA shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.93x
Galapagos NV's market cap is 1.93 times its annual revenue
Latest Price to Earnings (P/E) Ratio
6.67x
Galapagos NV's market cap is 6.67 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $4.68 Billion | $129.52 Million | $54.01 Million | 36.14x | 86.67x |
| 2017 | $6.07 Billion | $127.09 Million | -$115.70 Million | 47.76x | N/A |
| 2018 | $5.89 Billion | $288.84 Million | -$29.26 Million | 20.40x | N/A |
| 2019 | $14.33 Billion | $844.99 Million | $149.84 Million | 16.96x | 95.63x |
| 2020 | $5.97 Billion | $478.05 Million | -$305.44 Million | 12.49x | N/A |
| 2021 | $3.54 Billion | $484.85 Million | -$103.23 Million | 7.31x | N/A |
| 2022 | $3.07 Billion | $505.28 Million | -$217.99 Million | 6.07x | N/A |
| 2023 | $2.70 Billion | $239.72 Million | $211.70 Million | 11.25x | 12.74x |
| 2024 | $1.99 Billion | $275.65 Million | $74.08 Million | 7.21x | 26.83x |
| 2025 | $2.14 Billion | $1.11 Billion | $320.88 Million | 1.93x | 6.67x |
Competitor Companies of GXEA by Market Capitalization
Companies near Galapagos NV in the global market cap rankings as of November 4, 2026. Also see Galapagos NV asset portfolio for a full breakdown of the balance sheet.
Key companies related to Galapagos NV by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Galapagos NV (2015–2026)
Market capitalization of Galapagos NV from 2015 to today. Between 2015 and today, Galapagos NV's market cap moved from $4.36 Billion to $ 2.22 Billion, with a yearly change of -3.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.22 Billion | +3.60% |
| 2025 | €2.14 Billion | +7.75% |
| 2024 | €1.99 Billion | -26.29% |
| 2023 | €2.70 Billion | -12.06% |
| 2022 | €3.07 Billion | -13.48% |
| 2021 | €3.54 Billion | -40.65% |
| 2020 | €5.97 Billion | -58.33% |
| 2019 | €14.33 Billion | +143.14% |
| 2018 | €5.89 Billion | -2.90% |
| 2017 | €6.07 Billion | +29.66% |
| 2016 | €4.68 Billion | +7.37% |
| 2015 | €4.36 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Galapagos NV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.60 Billion USD |
| MoneyControl | $1.60 Billion USD |
| MarketWatch | $1.60 Billion USD |
| marketcap.company | $1.60 Billion USD |
| Reuters | $1.60 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Galapagos NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in… Read more